ImmunityBio stock surges 6.91% to close at $9.44, touches $10 intraday for first time since March

ImmunityBio stock surged 6.91% to close at $9.44 on Wednesday, breaching $10 intraday for the first time since March. That breakout through a level untouched for months now anchors the bullish case building across the daily chart.

Key takeaways

• ImmunityBio stock closed at $9.44 on Wednesday, up 6.91%, after touching $10.09 intraday — the first breach of $10 since March.
• The daily chart shows a fully stacked bullish EMA alignment: 20-session at $8.48, 50-session at $8.14, and 200-session at $6.63.
• Daily RSI14 at 64.57 signals strong momentum without being overbought, leaving room for further upside.
• The close above the upper daily Bollinger Band at $9.25 indicates expanding upside volatility, though a near-term pause is possible.
• Reclaiming the daily pivot at $9.48 on a closing basis is key to confirming the breakout and targeting $10.05 resistance.

Daily Structure Turns Decisively Bullish for ImmunityBio Stock

The daily structure now decisively favors buyers. ImmunityBio stock sits above the 20-session EMA at $8.48, which in turn sits above the 50-session EMA at $8.14. The 50-session EMA itself sits above the 200-session EMA at $6.63. This is a fully stacked bullish alignment — the kind of setup that attracts trend-following flow. The daily RSI14 at 64.57 backs this up: strong, but not yet overbought, leaving room for the move to extend.

Momentum Indicators Reinforce the Breakout

Momentum indicators reinforce the bullish read. MACD on the daily chart stands at 0.28 against a signal of 0.21, producing a positive histogram of 0.07. Momentum is positive and has not rolled over. Notably, the close at $9.44 pushed through the upper Bollinger Band at $9.25. A close outside the upper band after a near-7% session signals expanding upside volatility rather than exhaustion. Still, it raises the odds of a near-term pause as the band catches up with price.

The daily ATR14 reads 0.57, and the session’s $1.19 high-low spread confirms volatility has stepped up materially. The daily pivot sits at $9.48, with resistance at $10.05 (R1) and support at $8.86 (S1). Wednesday’s close at $9.44 landed just below that pivot despite the session’s strength. Reclaiming $9.48 on a closing basis would argue for a more decisive push toward the $10.05 resistance.

Multi-Timeframe Analysis of ImmunityBio Stock

The hourly chart confirms the bullish daily read with another fully stacked EMA alignment. Price at $9.43 sits above the 20-hour EMA at $9.17. That sits above the 50-hour EMA at $8.86, which sits above the 200-hour EMA at $8.30. The hourly RSI14 at 59.91 is constructive without being stretched. MACD mirrors the daily reading almost exactly: a line of 0.28, a signal of 0.21, and a positive histogram of 0.07. Momentum has not diverged between the two timeframes.

Meanwhile, the hourly Bollinger setup leaves room to the upside. Price at $9.43 trades comfortably inside the bands, with the midline at $9.05 and the upper band at $10.00. Unlike the daily breakout, this gives the move breathing space before it would need to test resistance again. The hourly pivot sits at $9.50, with R1 at $9.59 and S1 at $9.34. Price hovers around the pivot zone, neither decisively above nor below it.

The 15-Minute Chart Signals Short-Term Digestion

However, the picture complicates on the 15-minute chart. This timeframe exists for execution timing, not trend direction. Here, price at $9.43 sits below the 20-period EMA at $9.61. Yet it remains above the 50-period EMA at $9.35 and the 200-period EMA at $8.82 — a mixed, non-aligned setup. The 15-minute RSI14 at 43.35 sits below the midpoint, and MACD has turned negative with a histogram of -0.07. Price has also slipped below the 15-minute lower Bollinger Band at $9.49.

Taken together, this points to a short-term pullback or consolidation following the sharp intraday advance. It is not a reversal of the broader trend. Therefore, the conflict across timeframes is a timing issue rather than a directional one. Daily and hourly structure both argue for continuation. The 15-minute chart simply reflects the market digesting a large single-day move before deciding its next step.

Fundamental Backdrop for IBRX

Beyond the chart, institutional interest adds a fundamental layer to the ImmunityBio story. A Yahoo Finance report noted that the GA-Courtenay Special Situations Fund favors ImmunityBio. The fund, managed by Green Ash Partners, describes this as a $5.8 billion cancer market opportunity.

Separately, a Yahoo Finance futures roundup published after Wednesday’s close flagged IBRX among stocks in focus. The roundup, which appeared heading into a jobs report, also noted a sharp climb in the 10-year Treasury yield. This provides useful macro context, though it cannot explain Wednesday’s session since it appeared after that close.

Bullish and Bearish Scenarios

The bullish scenario requires reclaiming the $9.48 daily pivot, while the bearish case needs a break below $8.48 to gain traction. Overall, the weight of evidence favors bulls across the daily and hourly timeframes.

For the bullish scenario to extend, ImmunityBio stock would need to reclaim the daily pivot at $9.48 and hold above it. This would open the path toward the $10.05 resistance (R1) and potentially retest the $10.09 intraday high already printed this week. Sustained hourly closes above the $9.50 pivot would support that continuation, provided the daily RSI stays below overbought extremes. A fresh push above the daily upper Bollinger Band on strong follow-through volume would add further conviction.

On the other hand, the bearish case would need a clear break of the daily EMA20 at $8.48. It would also require a loss of the $8.86 support (S1) to gain real traction. A failure to reclaim the daily pivot, combined with the hourly MACD histogram turning negative, would signal the breakout is losing force rather than consolidating. In that scenario, the move back toward $8.86 and the 50-session EMA at $8.14 would become the levels to watch.

Overall, the weight of evidence across the daily and hourly timeframes favors the bullish thesis for ImmunityBio stock. The 15-minute pullback reads as short-term digestion rather than a trend change. At the same time, the breakout above the upper daily Bollinger Band and the elevated ATR14 suggest volatility will stay elevated in either direction. Positioning around current levels requires acknowledging that uncertainty — the stock has just made a notable technical statement. However, what matters most is confirmation — a decisive close above the $9.48 pivot — rather than the move itself.

FAQ

What is the current trend for ImmunityBio stock?

The daily chart shows a fully stacked bullish EMA alignment with price above all three key moving averages. The RSI14 at 64.57 confirms strong momentum without being overbought, leaving room for the move to extend.

What resistance levels should investors watch?

The daily pivot at $9.48 is the immediate level to reclaim on a closing basis. Above that, R1 at $10.05 and the recent intraday high of $10.09 serve as the next key resistance targets for ImmunityBio stock.

Is the 15-minute pullback a cause for concern?

The 15-minute pullback reflects short-term digestion following a sharp advance, not a trend reversal. Daily and hourly timeframes both maintain bullish alignment, making this a timing issue rather than a directional shift.

What would invalidate the bullish thesis?

A clear break below the daily EMA20 at $8.48 and a loss of S1 support at $8.86 would signal the breakout is losing force. In that scenario, a move toward the 50-session EMA at $8.14 would become the level to watch.

Article produced with the assistance of artificial intelligence and reviewed by the editorial team.